Insect Cell Culture Seed Expansion Patents: Leaders & White Space 2026
- Concentrated but not locked up. the top 5 of 98 ranked assignees hold 33.0% of all 224 records in scope, and the top 10 hold 54.9% — leaving a long tail of single- and few-filing entrants.
- Filings are still climbing. activity rose from 6 records in 2021 to 10 in 2024, a 67% increase over that span, with 2024 the last year publication lag lets you read cleanly.
- Claim density sits outside the obvious classes. 97.3% of records touch C12N, but measurement and testing (G01N, 8.5%) and the therapeutic-activity class A61P (18.3%) are comparatively thin — that is where open claim space concentrates.
Filing growth compares 2021 (6 records) with 2024 (10) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 224 records in scope (CR5), not by the ranked leaders only.
What this patent set covers
This landscape tracks 224 published records at the intersection of insect cell and baculovirus culture practice — seeding density, passage number, viability thresholds, doubling time, inoculum train design and culture transition — filtered against the core biologics-production IPC classes C12N5/06, C12N7/00 and C12M3/00. The scope favours process and cell-line engineering claims over end-product biologics claims, which is why C12N dominates the technology mix while therapeutic-activity classifications sit further down the list.
Records span filings from 2015 through the 2026 cut-off, drawn from receiving offices led by the United States, WIPO's PCT route, and the European Patent Office. Because publication trails filing by roughly 18 months, the most recent one to two years in any trend understate real filing activity — read 2024 as the last complete signal rather than the newest one.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology mix
Two views of the same 224-record corpus: how filing activity has moved year over year, and which IPC subclasses carry the claim density.
A growing but still modest filing pace
Filings moved from 6 records in 2021 to a peak of 10 in 2024, a 67% rise over three years. 2025 and 2026 figures will continue to fill in as later-filed applications publish, so treat the tail of the chart as incomplete rather than declining.
Where the claims sit across IPC subclasses
C12N accounts for 97.3% of the 224 records, confirming this is fundamentally a cell-line and microorganism engineering field. A61K (47.8%) and C07K (46.0%) show the biologics-production overlap, while G01N (8.5%) and C12R (14.7%) mark thinner, less-claimed territory around measurement and strain classification.
Shares are the percentage of the 224 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Insect Cell Culture Seed Expansion with Eureka
This page is one run against one query. Ask Eureka your own question about insect cell culture seed expansion and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
US9611455B2 — Adapted lepidopteran insect cells for the production of recombinant proteins
The patent covers raising culture pH above standard insect cell culture conditions during baculovirus infection of lepidopteran cells to enable production of recombinant chikungunya virus-like particles, together with insect cell lines (derived from lines such as Sf21) adapted to grow robustly at that elevated pH and to correctly fold pH-sensitive recombinant proteins.Filed by Merck Sharp & Dohme LLC; published 2017-04-04.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6534055B1 | Methods for selectively stimulating proliferation of T cells | 2,048 |
| 2 | US6905680B2 | Methods of treating HIV infected subjects | 1,820 |
| 3 | US5162222A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or reco… | 468 |
| 4 | US5077214A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells | 256 |
| 5 | US5300435A | Trichoplusia ni cell line which supports replication of baculoviruses | 242 |
| 6 | US6103526A | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using | 234 |
| 7 | WO1988007082A1 | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides | 224 |
| 8 | WO1996006161A1 | Establishment of trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus prod… | 199 |
| 9 | US6355479B1 | MHC class II antigen-presenting systems and methods for activating CD4+ T cells | 191 |
| 10 | WO2006071563A2 | Non-tumorigenic MDCK cell line for propagating viruses | 142 |
Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three read-throughs of the concentration, growth and technology figures above, translated into what they imply for a freedom-to-operate or filing decision.
A moderate lead, not a lock
The leading assignee holds 18 records and the top 5 combined hold 74 — 33.0% of all 224 records in scope. That is enough to dominate specific claim language but far short of the 54.9% held by the top 10, meaning the middle of the ranking still has room to build a defensible position.
Filing pace is still rising
Activity climbed from 6 records in 2021 to 10 in 2024. That is a real increase, not a plateau, and it argues against treating this as a mature, closed-out field — new entrants are still finding room to file.
Measurement and testing claims are thin
Only 19 of 224 records touch G01N (material analysis and testing), against 218 in C12N. Process-monitoring and in-line viability or density measurement claims are comparatively under-filed relative to the core cell-line and culture-method claims.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to insect cell culture seed expansion, with the prior art for and against each one.
Who is filing, and where the gaps are
The ranking spans 98 companies counted by record; the figures below describe the shape of that ranking rather than naming every entrant.
One clear leader, then a fast drop-off
The top-ranked assignee holds 18 of the 224 records. By fifth place that figure has fallen to 12, and by tenth place to 7 — a steep early drop that flattens into a long tail of smaller filers.
Historic leaders have gone quiet recently
Several assignees that built early positions in this space show zero filings in the latest year, including one with a -100% year-on-year drop. That does not mean the underlying IP has lapsed — it means recent filing activity has shifted toward other entrants.
Filing strategy is US- and PCT-centred
The United States leads receiving offices with 74 records, followed by WIPO's PCT route at 35 and the EPO at 33. Australia, Canada and Israel each carry smaller but non-trivial volumes, suggesting deliberate multi-jurisdiction strategies rather than purely domestic filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Boyce Thompson Institute for Plant Research, Inc. | 0 | — |
| Pharmacia & Upjohn Company LLC | 0 | — |
| The Scripps Research Institute | 0 | — |
| MedImmune LLC | 0 | — |
| GlycoBac LLC | 0 | — |
| Serum Institute of India Pte Ltd | 0 | -100% |
| The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | 0 | — |
| Cetus Corporation | 0 | — |
Where to take this analysis
The figures above describe the shape of the field. Turning that into a filing or licensing decision means drilling into specific claims and specific competitors.
Map claim overlap on a candidate filing
Run a draft claim set against the most-cited records in this corpus to see where seeding density or viability threshold language already sits on dense prior art.
Explore claim mapping in EurekaTrack the assignees still filing
Several early leaders show no recent activity while others keep filing — set up monitoring on the active group rather than the historic one.
Set up assignee tracking in EurekaTest white space before drafting
In-line viability sensing and inoculum train scale-down show comparatively low filing density; validate that gap against full claim text before committing drafting resources.
Search white space in EurekaCommon questions about this landscape
The dataset ranks 98 companies by record count, with the leading assignee holding 18 of the 224 records in scope. The top 5 assignees together account for 33.0% of all records, and the top 10 account for 54.9%, which means concentration is real at the very top but drops off quickly — by the tenth-ranked assignee the count is down to 7 records. This is not a field with a single dominant gatekeeper; it has a strong leader and a wide field of smaller filers behind it.
Filing activity grew from 6 records in 2021 to 10 in 2024, a 67% increase over that three-year span, and 2024 is the most recent year that can be read as complete. Publication typically lags actual filing by around 18 months, so the apparent drop in 2025 and 2026 numbers reflects records still working through publication, not a real slowdown. Based on the complete years, the trend points upward rather than flat or declining.
US9611455B2, assigned to Merck Sharp & Dohme LLC and published in 2017, covers raising culture pH above standard conditions during baculovirus infection of lepidopteran insect cells, plus insect cell lines derived from lines such as Sf21 that are adapted to grow well at that elevated pH. It is specifically tied to producing pH-sensitive recombinant proteins, including chikungunya virus-like particles, in the correct conformation. Anyone working on elevated-pH culture conditions or pH-adapted cell line derivatives for recombinant VLP production should check their process parameters against this claim scope directly.
Measurement and testing claims are comparatively thin: only 19 of the 224 records touch IPC class G01N, against 218 touching the core C12N class. Sub-areas such as in-line viability sensing, passage-number-triggered process control, and inoculum train scale-down modelling show lower filing density than the core cell-line and culture-method claims. That gap does not guarantee freedom to operate, but it does suggest less prior art to design around if a claim there is well drafted and technically specific.
The United States leads with 74 records, followed by the WIPO PCT route at 35 and the European Patent Office at 33; Australia, Canada and Israel each carry smaller volumes of 22, 17 and 14 respectively. That spread indicates that serious filers in this space are pursuing multi-jurisdiction protection rather than relying on a single domestic filing. Any competitive monitoring or freedom-to-operate check should cover at least the US, PCT and EPO filings to get a representative view.
Research Insect Cell Culture Seed Expansion in depth with Eureka
Go past this page: query the whole insect cell culture seed expansion corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.